Venus Concept (VERO) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
1 Feb, 2026Executive summary
Q2 2024 revenue was $16.6 million, down 17% year-over-year, mainly due to tighter credit markets, restructuring, and exit from unprofitable international markets, but in line with guidance.
Net loss attributable to stockholders was $20 million ($3.05/share), compared to $7.4 million ($1.35/share) in Q2 2023, driven by a $10.9 million non-cash pre-tax loss on debt extinguishment.
Adjusted EBITDA loss was $4.1 million, up 4% year-over-year; operating loss reduced by 3% to $5.6 million.
Cash used in operations for Q2 was $1.3 million, a 37% year-over-year reduction; for H1 2024, cash used in operations was $4.2 million, a 47% reduction.
Company continues to review strategic alternatives, including financings, mergers, or asset sales, to maximize shareholder value.
Financial highlights
Q2 2024 revenue was $16.6 million, down from $20.1 million in Q2 2023; US revenue declined 5% to $9.3 million, international revenue declined 29% to $7.3 million.
Gross margin improved to 71.5% from 70.8% in Q2 2023.
Operating expenses fell 13% to $17.4 million; selling/marketing down 16%, G&A down 10%.
Cash and equivalents were $5.7 million as of June 30, 2024; total debt was $46 million, down from $74.9 million at year-end 2023.
Lease program revenues accounted for 34% of system revenues in Q2 2024, up from 26% a year ago.
Outlook and guidance
No full-year 2024 financial guidance provided due to ongoing strategic review and lender discussions.
Q3 2024 revenue expected to be at least $17 million, a 3% sequential increase.
Targeting cash flow breakeven in the second half of 2025.
Management expects continued macroeconomic headwinds, high interest rates, and inflation to impact demand and financing.
Some supply chain challenges anticipated in H2 2024 due to geopolitical disruptions.
Latest events from Venus Concept
- Q3 2024 revenue fell 15% year-over-year as debt was cut by 54% and losses persisted.VERO
Q3 202414 Jan 2026 - Revenue fell 13% in Q4 and 15% for FY24; debt cut by 47% and Q1 2025 revenue to exceed $14M.VERO
Q4 202424 Dec 2025 - Shelf registration enables up to $30.4M in securities sales for global medical technology expansion.VERO
Registration Filing16 Dec 2025 - Shareholders to vote on director elections, auditor ratification, and key share issuance proposals.VERO
Proxy Filing1 Dec 2025 - Shareholders to vote on director elections, auditor ratification, and major share issuances.VERO
Proxy Filing1 Dec 2025 - Vote sought on a reverse stock split to maintain Nasdaq listing and avoid delisting risk.VERO
Proxy Filing1 Dec 2025 - Vote sought to authorize a reverse stock split to maintain Nasdaq listing and enhance share value.VERO
Proxy Filing1 Dec 2025 - Approval sought for share issuance tied to convertible notes after major debt restructuring.VERO
Proxy Filing1 Dec 2025 - Amended registration statement for a public offering, with auditor consent and executive sign-off.VERO
Registration Filing29 Nov 2025